CLGNNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31

CollPlant Biotechnologies Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026

$3.56−0.06 (-1.79%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

CollPlant Biotechnologies Ltd balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Cash & Equivalents	5.59	12	27	30	13	3.53	3.79	5.66	5.28	1.32
Cash & Short-Term Investments	5.59	12	27	30	13	3.53	3.79	5.66	5.28	1.32
Receivables	0.00	0.15	–	0.01	0.27	0.83	0.08	–	–	–
Inventory	0.57	0.44	0.71	1.43	1.08	1.26	0.89	0.81	0.20	–
Prepaid Expenses & Other	0.22	0.43	0.39	0.54	0.42	0.24	0.27	–	–	–
Total Current Assets	6.75	13	28	32	45	5.68	5.04	7.17	6.47	–
Property, Plant & Equipment	1.46	2.29	2.79	2.97	2.73	2.11	2.33	1.41	1.03	–
Gross Property, Plant & Equipment	9.34	9.31	8.84	8.01	6.74	5.59	5.15	–	–	–
Accumulated Depreciation	-7.88	-7.02	-6.05	-5.04	-4.01	-3.48	-2.82	–	–	–
Equity Method Investments	–	–	0.00	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	2.43	2.99	3.07	2.71	2.95	2.80	3.22	3.47	–	–
Intangible Assets	0.07	0.13	0.19	0.25	0.24	0.08	–	–	–	–
Total Assets	11	19	34	38	51	11	11	8.75	8.09	–
Short-Term Debt	–	–	–	0.32	0.22	–	–	–	–	–
Current Debt	–	–	–	0.32	0.22	–	–	–	–	–
Current Portion of Leases	0.81	0.81	0.62	0.53	0.52	0.44	0.46	0.48	–	–
Deferred Revenue (Current)	–	–	–	–	0.03	0.21	0.94	0.97	–	–
Total Current Liabilities	2.67	2.97	3.25	3.11	3.01	3.39	3.46	2.23	1.42	–
Long-Term Leases	2.03	2.28	2.54	2.38	3.09	2.95	3.14	3.01	–	–
Operating Lease Liabilities	2.85	3.08	3.16	2.91	3.61	3.39	3.59	3.49	–	–
Total Liabilities	4.70	5.25	5.79	5.49	6.10	6.36	6.66	3.33	5.47	–
Total Debt	–	–	–	0.32	0.22	–	–	–	–	–
Common Stock	5.49	4.98	4.98	4.87	4.66	2.93	2.37	–	–	–
Additional Paid-In Capital	126	123	121	118	–	–	–	–	–	–
Retained Earnings	-125	-113	-97	-90	-73	-73	-67	-56	-50	–
Comprehensive Income & Other	-0.97	-0.97	-0.97	-0.97	–	–	–	–	–	–
Shareholders' Equity	6.08	13	28	32	45	4.48	4.09	5.42	5.17	–
Total Equity	6.08	13	28	32	45	4.48	4.09	5.42	5.17	1.49
Total Liabilities & Equity	11	19	34	38	51	11	11	8.75	8.09	–
Shares Outstanding(shares)	1.28	1.15	1.15	1.12	1.08	0.70	0.57	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 64.8%
Operating margin: -484.3%
Net margin: -484.6%
Return on equity, FY2025: -117.6%

Financial strength

Current ratio: 1.57
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 102.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –